The Food and Drug Administration (FDA) decided by a margin
of 16 to 1 to continue observing the safety of anti-psychotic drugs such as
Abilify in children. Statistics indicate
a rise of 65% of prescribing the drugs among teens in 2002-2009. From fall 2009 until 2011, 1.9 million prescriptions
were given for children 18 and under.
The FDA will be focusing on how to simplify their
labels. They will also showcase their
worries of the effects of the drugs on children. The FDA will primarily focus in two areas:
weight gain and diabetes.
New labels on the drugs will highlight the drug’s most
recent testing. They will caution about
metabolism problems. The labels will
also tell doctors to watch for weight gain and signs of diabetes.
The new wave of anti-psychotic drugs among children has been
known to cause alarm for support systems.
They are continuously being given to young children. There isn’t much data proving that the drugs
help, as well as inconclusive evidence showing the effects among children.
New FDA labels: http://www.reuters.com/article/2011/09/22/us-usa-fda-antipsychotic-idUSTRE78L77L20110922
No comments:
Post a Comment